Similar Items: Anti‐amyloid therapy eligibility in a longitudinal brain‐donor cohort with post mortem confirmation
- Eligibility for anti‐amyloid treatment in a multiethnic community‐based study
- Clinical and MRI features associated with amyloid positivity in secondary screening for anti–amyloid‐β therapy
- White matter hyperintensities in Alzheimer's disease in the era of anti‐amyloid therapies
- Identification of patients receiving amyloid‐targeting therapies in observational studies using amyloid PET trajectories: Insights from LEADS
- “Doctor, if it were you, which would you choose?”: Navigating personal preference questions in anti‐amyloid immunotherapy selection
- Obstacles and solutions for implementing amyloid‐targeting treatments in Europe